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Introduction
The aetiology of breast cancer is complex but involves
selection of variant cells that develop a growth advantage
over and above that of the surrounding normal epithelium.
The growth advantage must be a combination of increased
proliferation and decreased apoptosis to allow cell survival.
Comparison of normal breast tissue around cancer with
breast reduction derived epithelium [1] indicated that it is
mainly decreased apoptosis rather than increased
proliferation that is seen in the normal epithelium in
malignant breasts. Bypassing senescence and inhibiting
apoptosis permits the accumulation of genomic alterations
that push a cell toward a malignant phenotype.
A recent report from Crawford and coworkers [2]
compared genes expressed in normal and variant human
mammary epithelial cells (HMECs). It identified that, as
well as silencing the INK4a gene through promoter
methylation, the variant cells over-express cyclo-
oxygenase (COX)-2.
Variant human mammary epithelial cells
Primary culture of breast tissue from normal women yields
HMECs, which senesce after 10–15 population doublings
in culture. However, a subpopulation termed variant
HMECs are capable of proliferating for an additional
30–50 generations, and reach a plateau of high
proliferation and high apoptosis termed agonescence in
which the cell population does not increase but sustains
itself.
Nearly 100% of these variant HMECs exhibit telomeric
dysfunction and chromosomal defects as they approach
agonescence. Many of these defects are similar to those
seen in the earliest lesions of breast malignancy, and
Crawford and coworkers have already described this
variant HMEC population to contain cells with
hypermethylated INK4a promoter sequences, which leads
to loss of p16INK4A protein and allows increased cell
cycling through cyclin D1. The variant HMECs also over-
express the COX-2 protein.
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A recent report suggests that, in an in vitro model of premalignant breast cells (vHMECs), silencing of
INK4A gene is accompanied by over-expression of cyclo-oxygenase (COX)-2. This suggests that
COX-2 over-expression may be an early event in breast cancer aetiology permitting clones within the
normal epithelium to evade apoptosis, to increase their numbers and perhaps acquire further changes
that promote the formation of hyperplasias, and eventually carcinomas. While COX-2 expression in
normal breast epithelium in vivo has not been proven to be linked to an increased risk of breast cancer,
its over-expression in the premalignant model in vitro does provide preliminary evidence that COX-2
inhibition may be a useful chemoprevention strategy.
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One limitation in relating variant HMECs to premalignant
lesions  in vivo is that there is no cell purification step
during isolation of HMECs and it is well recognized that
this leads to mixed populations of myoepithelial and luminal
cells. It is therefore possible that some variant HMECs in
vitro are myoepithelial cells and thus they may be unrelated
to the luminal cells that comprise most premalignant
lesions  in vivo. Second, there is no proof that the p16
promoter-methylated cells observed in the breast in vivo
are the cells of origin of variant HMECs in culture.
Paradoxically, Crawford and coworkers [2] reported that
methylation of the p16 promoter was found in only three
out of 10 breast samples examined, yet variant HMECs can
be cultured from all reduction mammoplasty samples.
Cyclo-oxygenase-2 and breast cancer
COX-2 is an inducible enzyme that is responsible for the
conversion of arachidonic acid to prostaglandins
(including prostaglandin E2 and thromboxane) and leading
to inflammatory responses in tissues. Transgenic mice
engineered to over-express COX-2 have increased
development of breast cancer and their breast epithelial
cells show reduced apoptosis [3]. Expression of COX-2 is
common, with over 80% of ductal carcinoma in situ and
40% of invasive breast cancers having the protein. Human
breast tumours that are COX-2 positive have high grade,
proliferation and oestrogen receptor (ER)-negative status,
and are associated with shorter time to recurrence and
death [4]. COX-2 over-expression in epithelial cells leads
to increased prostaglandin E2 secretion and increased
matrix metalloproteinase (MMP)-9 release [5]. MMP-9
activity shears cell-bound transforming growth factor-α,
which transactivates the epidermal growth factor receptor,
and epidermal growth factor receptor/c-erbB2 hetero-
dimers, leading to a positive feedback loop in which cells
exhibit increased proliferation and reduced apoptosis.
COX-2 positive cells show increased aromatase activity
due to the release of prostaglandins, increasing aromatase
in surrounding stroma and epithelium, leading to synthesis
of oestrogens in the microenvironment around COX-2
over-expressing cells [6]. It appears, however, that it is
largely ER-positive breast cancer development that is
inhibited by nonsteroidal anti-inflammatory drugs [7].
Increased aromatase activity promotes the growth of ER-
positive breast cells, and this is of particular relevance to
postmenopausal breast cancer, in which systemic
oestrogens are low. Recent epidemiological studies have
indicated that there is a reduced incidence of breast
cancer in women taking aspirin or other nonsteroidal anti-
inflammatory drugs (that inhibit COX-2).
Invasive events in normal breast epithelium
leading to cancer diagnosis
The report that COX-2 over-expression is an important
early event in the aetiology of breast cancer is very
important [2]. COX-2 over-expression would potentially
permit clones within the normal epithelium to evade
apoptosis, increase their number and eventually occupy
luminal spaces where cells would normally undergo
anoikis. In normal breast epithelium expressing COX-2,
Boland and coworkers [8] showed higher proliferation.
COX-2 is a strong candidate for a gene that is intrinsically
involved in this process and small molecule inhibitors are
readily available. It is not yet clear whether COX-2 or
hypermethylation of the INK4a promoter is the first step
that allows cells to progress to cancer. COX-2 expression
is induced both by the RAS/mitogen-activated protein
kinase signalling pathway and by inflammatory stimuli,
including carcinogens that increase tumour necrosis
factor-induced nuclear factor-κB activation. Increased
expression of cyclin D1, COX-2, MMP-9 and several
inhibitors of apoptosis proteins (including survivin and
IAP1) is often seen with nuclear factor-κB stimulus. These
changes can be reversed by RAS farnesyl transferase
inhibitors, which induce apoptosis and inhibit
angiogenesis. It may be that all of these observed changes
relate fundamentally to the underlying carcinogenic stimuli
that these breasts are subject to, such as tobacco smoke,
chemicals, or radiation.
Conclusion
At present, the concept that variant HMECs are a
precursor cell for either atypical lesions, in situ disease, or
even cancer is unproven, and neither have Crawford and
coworkers [2] shown that women with COX-2 expression
in the majority of epithelial cells in the breast have a
subsequently increased risk for breast cancer. These are
both fundamental to their argument that such changes
promote a premalignant programme. Such evidence will
be necessary if we are to pursue a programme
investigating COX-2 inhibition as chemoprevention for
premenopausal breast cancer. Chemoprevention studies
take years to come to fruition. Therefore, further ‘in vitro’ or
‘in vivo’ laboratory studies of agents such as celecoxib, a
selective COX-2 inhibitor that can inhibit cancer
development in mouse models of mammary cancer
including the CerbB2 transgenic mouse [9], now need to
be backed up with short-term clinical trials. These should
test the effects of COX-2 inhibition on the normal breast,
particularly whether COX-2 expression is switched off by
treatment and whether switch-off leads to increased
apoptosis in the normal epithelium.
In addition, studies of normal breast biopsies in women
who subsequently went on to develop breast cancer will
be important in determining whether COX-2-related
changes occurred in these women but not in a population
in which cancer did not develop after biopsy. Further
clarification of the nature of variant HMEC cells and how
they relate to stem cells will also be important. The recent
recognition of stem cells within the human breast20
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indicates that it may often be damage to these stem cells
that is fundamental to the development of cancer.
Evidence of the same abnormalities in stem cells from
breasts that subsequently develop cancer would also be
persuasive. Current chemoprevention strategies have
used anti-oestrogens such as tamoxifen, raloxifene, or
aromatase inhibitors to inhibit breast proliferation that
occurs via an ER-dependent mechanism. These studies
only prevent ER-positive breast cancer, but agents that
increase apoptosis such as the COX-2 inhibitors will
potentially inhibit both ER-positive and ER-negative breast
cancer with minimal toxicity. A greater understanding of
how to increase apoptosis in the breast may well be the
missing piece in the puzzle of how to prevent breast
cancer development.
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